Monte Rosa Therapeutics More Than Doubles on Novartis Agreement

Dow Jones10-29

By Josh Beckerman

Shares of Monte Rosa Therapeutics more than doubled and touched a 52-week high after the biotechnology company reported a global exclusive development and commercialization license agreement with Novartis.

Monte Rosa stock was up 130%, to $11.25, on Monday, with an intraday high of $12.15, and is up about 103% this year.

Terms include a $150 million up-front payment from Novartis. Monte Rosa is eligible to receive up to $2.1 billion in development, regulatory, and sales milestones.

Novartis will obtain exclusive worldwide rights to develop, manufacture and commercialize MRT-6160 and other VAV1-directed molecular glue degraders.

MRT-6160 is currently in a continuing Phase 1 healthy volunteer study for immune-mediated conditions.

TD Cowen maintained its "buy" rating for Monte Rosa. It said the licensing agreement provides validation for the MRT-6160 program and said it believes the economics of the agreement are favorable.

Write to Josh Beckerman at josh.beckerman@wsj.com

(END) Dow Jones Newswires

October 28, 2024 14:31 ET (18:31 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2479643453?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-10-29 02:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2479643453","market":"us","top_or_hot":-1,"title":"Monte Rosa Therapeutics More Than Doubles on Novartis Agreement","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Josh Beckerman \n</p>\n<pre>\n \n</pre>\n<p>\n  Shares of <a href=\"https://laohu8.com/S/GLUE\">Monte Rosa Therapeutics</a> more than doubled and touched a 52-week high after the biotechnology company reported a global exclusive development and commercialization license agreement with Novartis. \n</p>\n<p>\n  Monte Rosa stock was up 130%, to $11.25, on Monday, with an intraday high of $12.15, and is up about 103% this year. \n</p>\n<p>\n  Terms include a $150 million up-front payment from Novartis. Monte Rosa is eligible to receive up to $2.1 billion in development, regulatory, and sales milestones. \n</p>\n<p>\n  Novartis will obtain exclusive worldwide rights to develop, manufacture and commercialize MRT-6160 and other VAV1-directed molecular glue degraders. \n</p>\n<p>\n  MRT-6160 is currently in a continuing Phase 1 healthy volunteer study for immune-mediated conditions. \n</p>\n<p>\n  TD Cowen maintained its \"buy\" rating for Monte Rosa. It said the licensing agreement provides validation for the MRT-6160 program and said it believes the economics of the agreement are favorable. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Josh Beckerman at josh.beckerman@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  October 28, 2024 14:31 ET (18:31 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Monte Rosa Therapeutics More Than Doubles on Novartis Agreement</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMonte Rosa Therapeutics More Than Doubles on Novartis Agreement\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-10-29 02:31 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://dowjonesnews.com/newdjn/logon.aspx?AL=N><strong>Dow Jones</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>By Josh Beckerman \n\n\n \n\n\n  Shares of Monte Rosa Therapeutics more than doubled and touched a 52-week high after the biotechnology company reported a global exclusive development and commercialization ...</p>\n\n<a href=\"https://dowjonesnews.com/newdjn/logon.aspx?AL=N\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4539","symbol_name":"次新股","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2479643453","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2479643453","pubTimestamp":1730140260,"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Monte Rosa Therapeutics more than doubled and touched a 52-week high after the biotechnology company reported a global exclusive development and commercialization license agreement with Novartis.Monte Rosa stock was up 130%, to $11.25, on Monday, with an intraday high of $12.15, and is up about 103% this year.Terms include a $150 million up-front payment from Novartis. Monte Rosa is eligible to receive up to $2.1 billion in development, regulatory, and sales milestones.Novartis will obtain exclusive worldwide rights to develop, manufacture and commercialize MRT-6160 and other VAV1-directed molecular glue degraders.MRT-6160 is currently in a continuing Phase 1 healthy volunteer study for immune-mediated conditions.TD Cowen maintained its \"buy\" rating for Monte Rosa. It said the licensing agreement provides validation for the MRT-6160 program and said it believes the economics of the agreement are favorable.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4539":"次新股","GLUE":"Monte Rosa Therapeutics","BK4139":"生物科技"},"translate_title":"Monte Rosa Therapeutics与诺华的协议增加了一倍多","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GLUE":1},"content_text":"By Josh Beckerman \n\n\n \n\n\n  Shares of Monte Rosa Therapeutics more than doubled and touched a 52-week high after the biotechnology company reported a global exclusive development and commercialization license agreement with Novartis. \n\n\n  Monte Rosa stock was up 130%, to $11.25, on Monday, with an intraday high of $12.15, and is up about 103% this year. \n\n\n  Terms include a $150 million up-front payment from Novartis. Monte Rosa is eligible to receive up to $2.1 billion in development, regulatory, and sales milestones. \n\n\n  Novartis will obtain exclusive worldwide rights to develop, manufacture and commercialize MRT-6160 and other VAV1-directed molecular glue degraders. \n\n\n  MRT-6160 is currently in a continuing Phase 1 healthy volunteer study for immune-mediated conditions. \n\n\n  TD Cowen maintained its \"buy\" rating for Monte Rosa. It said the licensing agreement provides validation for the MRT-6160 program and said it believes the economics of the agreement are favorable. \n\n\n \n\n\n  Write to Josh Beckerman at josh.beckerman@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  October 28, 2024 14:31 ET (18:31 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2479643453"}